ANXA9 and colitis: Anxa9, a novel marker associated with poor prognosis, was significantly upregulated in ERAP1+/− colitis mice compared to ERAP1+/− controls (p < 0.05), with a further significant increase observed following sulfasalazine treatment (p < 0.05) (Figure 7A).